Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:GHNYSE:HIMSNASDAQ:OPCHNASDAQ:VCYT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeGHGuardant Health$47.99-0.6%$43.35$17.52▼$50.89$5.01B1.452.14 million shs1.73 million shsHIMSHims & Hers Health$28.51+1.5%$33.44$11.20▼$72.98$6.33B1.6515.72 million shs32.72 million shsOPCHOption Care Health$32.97+0.2%$33.37$21.39▼$35.53$5.42B1.071.78 million shs2.80 million shsVCYTVeracyte$31.67-1.7%$32.04$19.48▼$47.32$2.47B2.03862,718 shs722,950 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceGHGuardant Health-0.64%+12.63%+11.24%-0.56%+176.60%HIMSHims & Hers Health+1.46%+10.03%-2.04%-9.37%+128.08%OPCHOption Care Health+0.21%+5.50%-5.07%+6.94%+11.35%VCYTVeracyte-1.74%+3.50%+5.15%-27.48%+64.01%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationGHGuardant Health3.9327 of 5 stars2.54.00.04.32.72.50.6HIMSHims & Hers Health3.7745 of 5 stars4.12.00.00.02.73.31.9OPCHOption Care Health3.0908 of 5 stars1.43.00.04.23.12.50.6VCYTVeracyte3.9424 of 5 stars4.41.00.04.31.90.80.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceGHGuardant Health 3.05Buy$49.002.10% UpsideHIMSHims & Hers Health 2.15Hold$38.0833.58% UpsideOPCHOption Care Health 2.75Moderate Buy$33.752.37% UpsideVCYTVeracyte 2.70Moderate Buy$42.6034.51% UpsideCurrent Analyst Ratings BreakdownLatest VCYT, HIMS, GH, and OPCH Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails4/25/2025HIMSHims & Hers HealthCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetSell ➝ Sell$27.00 ➝ $25.004/22/2025OPCHOption Care HealthJMP SecuritiesSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingMarket Outperform ➝ Market Outperform$36.00 ➝ $36.004/21/2025OPCHOption Care HealthBarrington ResearchSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$38.00 ➝ $38.004/10/2025GHGuardant HealthBarclaysSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$60.00 ➝ $55.004/10/2025GHGuardant HealthMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$55.004/10/2025HIMSHims & Hers HealthTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$39.00 ➝ $33.004/9/2025GHGuardant HealthMizuhoSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy4/9/2025VCYTVeracyteGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$45.00 ➝ $37.004/2/2025HIMSHims & Hers HealthCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell ➝ Sell3/26/2025GHGuardant HealthStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$55.00 ➝ $55.003/26/2025VCYTVeracyteStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$45.00 ➝ $45.00(Data available from 4/29/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookGHGuardant Health$739.02M8.01N/AN/A$1.34 per share35.81HIMSHims & Hers Health$1.48B4.29N/AN/A$1.61 per share17.71OPCHOption Care Health$5.00B1.08$1.92 per share17.19$8.03 per share4.11VCYTVeracyte$445.76M5.54$0.07 per share442.29$14.30 per share2.21Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateGHGuardant Health-$479.45M-$3.56N/AN/AN/A-59.05%-19,157.20%-25.96%4/30/2025 (Estimated)HIMSHims & Hers Health-$23.55M$0.5464.8054.83N/A8.19%10.97%8.29%5/5/2025 (Estimated)OPCHOption Care Health$267.09M$1.2227.7126.172.304.37%15.30%6.57%4/29/2025 (Estimated)VCYTVeracyte-$74.40M$0.30N/A43.99N/A-2.18%3.02%2.80%5/7/2025 (Estimated)Latest VCYT, HIMS, GH, and OPCH EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2025Q1 2025VCYTVeracyte$0.21N/AN/AN/A$110.81 millionN/A5/5/2025Q1 2025HIMSHims & Hers Health$0.11N/AN/AN/A$535.21 millionN/A4/30/2025Q1 2025GHGuardant Health-$0.57N/AN/AN/A$189.91 millionN/A4/29/2025Q1 2025OPCHOption Care Health$0.36N/AN/AN/A$1.26 billionN/A2/24/2025Q4 2024HIMSHims & Hers Health$0.09$0.11+$0.02$0.11$494.56 million$481.14 million2/24/2025Q4 2024VCYTVeracyte$0.29$0.36+$0.07$0.06$110.73 million$118.63 million2/20/2025Q4 2024GHGuardant Health-$0.75-$0.90-$0.15-$0.90$192.50 million$201.81 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthGHGuardant HealthN/AN/AN/AN/AN/AHIMSHims & Hers HealthN/AN/AN/AN/AN/AOPCHOption Care HealthN/AN/AN/AN/AN/AVCYTVeracyteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioGHGuardant HealthN/A6.225.85HIMSHims & Hers HealthN/A2.141.82OPCHOption Care Health0.771.731.32VCYTVeracyteN/A5.084.79Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipGHGuardant Health92.60%HIMSHims & Hers Health63.52%OPCHOption Care Health98.05%VCYTVeracyteN/AInsider OwnershipCompanyInsider OwnershipGHGuardant Health5.50%HIMSHims & Hers Health17.71%OPCHOption Care Health0.64%VCYTVeracyte1.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableGHGuardant Health1,790123.42 million116.76 millionNot OptionableHIMSHims & Hers Health650222.17 million179.79 millionOptionableOPCHOption Care Health5,600164.24 million169.09 millionOptionableVCYTVeracyte79077.95 million76.49 millionOptionableVCYT, HIMS, GH, and OPCH HeadlinesRecent News About These CompaniesBarclays PLC Boosts Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)April 28 at 3:49 AM | marketbeat.comWells Fargo & Company MN Acquires 11,387 Shares of Veracyte, Inc. (NASDAQ:VCYT)April 28 at 3:15 AM | marketbeat.comVeracyte expands Decipher Prostate test availabilityApril 26 at 8:25 AM | markets.businessinsider.comOberweis Asset Management Inc. Raises Stock Holdings in Veracyte, Inc. (NASDAQ:VCYT)April 26 at 7:27 AM | marketbeat.comLeerink Partnrs Has Pessimistic View of Veracyte Q1 EarningsApril 26 at 6:44 AM | marketbeat.comDark Forest Capital Management LP Buys New Position in Veracyte, Inc. (NASDAQ:VCYT)April 26 at 5:52 AM | marketbeat.comGuggenheim Capital LLC Purchases New Stake in Veracyte, Inc. (NASDAQ:VCYT)April 26 at 4:16 AM | marketbeat.comVeracyte Inc (VCYT) Launches Decipher Prostate Metastatic Genomic Classifier | VCYT stock newsApril 25, 2025 | gurufocus.comVeracyte Announces Expanded Availability of Decipher Prostate Test to Patients with Metastatic Prostate CancerApril 25, 2025 | businesswire.comQ2 Earnings Forecast for Veracyte Issued By Leerink PartnrsApril 25, 2025 | marketbeat.comSilverarc Capital Management LLC Boosts Holdings in Veracyte, Inc. (NASDAQ:VCYT)April 24, 2025 | marketbeat.comLeerink Partnrs Increases Earnings Estimates for VeracyteApril 24, 2025 | marketbeat.comFY2026 EPS Estimates for Veracyte Boosted by Leerink PartnrsApril 24, 2025 | americanbankingnews.comLeerink Partnrs Has Negative Outlook of Veracyte Q2 EarningsApril 24, 2025 | americanbankingnews.comVeracyte Announces Multiple Abstracts Demonstrating Power of Decipher Testing To Fuel New Prostate and Bladder Cancer Insights Will Be Presented at AUA Annual MeetingApril 22, 2025 | businesswire.comShort Interest in Veracyte, Inc. (NASDAQ:VCYT) Increases By 26.4%April 22, 2025 | marketbeat.comVeracyte Announces Decipher Prostate Genomic Classifier Results are Linked to Real-World Data in National Cancer Institute's SEER Specialized Database ReleaseApril 21, 2025 | businesswire.comZacks Investment Management Acquires 16,603 Shares of Veracyte, Inc. (NASDAQ:VCYT)April 21, 2025 | marketbeat.comMarshall Wace LLP Increases Stock Position in Veracyte, Inc. (NASDAQ:VCYT)April 21, 2025 | marketbeat.comChamplain Investment Partners LLC Cuts Stake in Veracyte, Inc. (NASDAQ:VCYT)April 20, 2025 | marketbeat.comRussell Investments Group Ltd. Acquires 45,876 Shares of Veracyte, Inc. (NASDAQ:VCYT)April 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesArcher Aviation Gets Analyst Target Upgrade: Time to Load Up?By Jeffrey Neal Johnson | April 25, 2025View Archer Aviation Gets Analyst Target Upgrade: Time to Load Up?5 Highest-Rated Dividend Stocks According to MarketBeatBy Thomas Hughes | April 10, 2025View 5 Highest-Rated Dividend Stocks According to MarketBeat5 Hot Stock Buys for Investors in AprilBy Thomas Hughes | April 1, 2025View 5 Hot Stock Buys for Investors in AprilAre Short Sellers Wrong About These 3 Semiconductor Stocks?By Leo Miller | April 4, 2025View Are Short Sellers Wrong About These 3 Semiconductor Stocks?Tesla Stock Eyes Breakout With Earnings on DeckBy Sam Quirke | April 16, 2025View Tesla Stock Eyes Breakout With Earnings on DeckVCYT, HIMS, GH, and OPCH Company DescriptionsGuardant Health NASDAQ:GH$47.99 -0.31 (-0.64%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$46.88 -1.11 (-2.30%) As of 04/28/2025 07:15 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Guardant Health, Inc., a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers. It offers Shield Test; Guardant Reveal Test for adjuvant treatment selection in early-stage cancer patients; Smart Liquid Biopsy Platform; and Guardant Galaxy, an AI-backed digital pathology platform that helps improve cancer biomarker detection. In addition, the company offers development services, including companion diagnostic development and regulatory approval, clinical study setup, monitoring and maintenance, testing development and support, technologies licensing, and kits fulfillment. The company has a collaboration agreement with Illumina, Inc. for the sharing of specimen samples to advance cancer research. The company was incorporated in 2011 and is headquartered in Palo Alto, California.Hims & Hers Health NYSE:HIMS$28.51 +0.42 (+1.50%) Closing price 04/28/2025 03:59 PM EasternExtended Trading$28.60 +0.08 (+0.30%) As of 04/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.Option Care Health NASDAQ:OPCH$32.97 +0.07 (+0.21%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$33.32 +0.34 (+1.05%) As of 04/28/2025 07:49 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Option Care Health, Inc. offers home and alternate site infusion services in the United States. The company provides anti-infective therapies; home infusion services to treat heart failures; home parenteral nutrition and enteral nutrition support services for numerous acute and chronic conditions, such as stroke, cancer, and gastrointestinal diseases; immunoglobulin infusion therapies for the treatment of immune deficiencies; and treatments for chronic inflammatory disorders, including crohn's disease, plaque psoriasis, psoriatic arthritis, rheumatoid arthritis, ulcerative colitis, and other chronic inflammatory disorders. It also offers treatments to manage the progression of neurological disorders, such as multiple sclerosis, duchenne muscular dystrophy, and other neurological disorder; infusion therapies for bleeding disorders, such as hemophilia and von Willebrand diseases; therapies for women with high-risk pregnancies; and other infusion therapies to treat various conditions, including pain management, chemotherapy, and respiratory medications, as well as nursing services. The company markets its services through patient referrals, including physicians, hospital discharge planners, hospital personnel, health maintenance organizations, and preferred provider organizations. Option Care Health, Inc. is headquartered in Bannockburn, Illinois.Veracyte NASDAQ:VCYT$31.67 -0.56 (-1.74%) Closing price 04/28/2025 04:00 PM EasternExtended Trading$31.59 -0.08 (-0.25%) As of 04/28/2025 05:16 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Veracyte, Inc. engages in the research, development and commercialization of diagnostic products. The firm's portfolio includes Afirma, Percepta, and Envisia. It intends to treat thyroid cancer, improve lung cancer screening, and clarify the diagnosis of idiopathic pulmonary fibrosis. The company was founded by Bonnie H. Anderson and Y. Douglas Dolginow on August 15, 2006 and is headquartered in South San Francisco, CA. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Alphabet Rebounds After Strong Earnings and Buyback Announcement Could Selling Taiwan Semiconductor Be Buffett’s Biggest Regret? The Bear Market Has Only Just Started - Here's Why MarketBeat Week in Review – 04/21 - 04/25 3 Top Big Pharma Stocks Investing Over $100 Billion in the U.S. PepsiCo’s Stock Price is Disconnected From Reality: Time to Buy Bears Can Reap Big Benefits With These 3 Short ETF Bets Why Institutions Are Buying Super Micro Computer Stock Again Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
